|
| 36287571 | A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary. | J Pathol | 2023 |
| 37657447 | Protein-encapsulated doxorubicin reduces cardiotoxicity in hiPSC-cardiomyocytes and cardiac spheroids while maintaining anticancer efficacy. | Stem Cell Reports | 2023 |
| 37175833 | Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies. | Int J Mol Sci | 2023 |
| 37104017 | Identification and Characterisation of Infiltrating Immune Cells in Malignant Pleural Mesothelioma Using Spatial Transcriptomics. | Methods Protoc | 2023 |
| 37474720 | Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial. | Br J Cancer | 2023 |
| 36720497 | Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. | J Immunother Cancer | 2023 |
| 36404632 | Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres. | Cancer Med | 2023 |
| 36627112 | Use of durvalumab in stage III non-small-cell lung cancer based on eligibility for the PACIFIC study. | Thorac Cancer | 2023 |
| 34216247 | First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. | Cancer Immunol Immunother | 2022 |
| 35844787 | TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity. | Int J Biol Sci | 2022 |
| 35804177 | Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study. | Support Care Cancer | 2022 |
| 35404393 | Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. | Cancer Discov | 2022 |
| 36192237 | A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. | Gynecol Oncol | 2022 |
| 35059200 | Nintedanib-A case of treating concurrent idiopathic pulmonary fibrosis and non-small cell lung cancer. | Respirol Case Rep | 2022 |
| 34274535 | A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth. | Mol Ther | 2022 |
| 32770720 | Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). | Clin Transl Sci | 2021 |
| 33545359 | circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGFβR1/VEGF-D signaling. | Mol Ther | 2021 |
| 33766079 | Correction to: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. | Breast Cancer Res | 2021 |
| 33510281 | Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment. | Sci Rep | 2021 |
| 33818870 | Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. | Oncologist | 2021 |
| 33836153 | Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. | Lancet Respir Med | 2021 |
| 33889439 | Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. | Oncoimmunology | 2021 |
| 33661764 | SUMOylation promotes extracellular vesicle-mediated transmission of lncRNA ELNAT1 and lymph node metastasis in bladder cancer. | J Clin Invest | 2021 |
| 33721613 | Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors. | Lung Cancer | 2021 |
| 34636747 | New therapeutic opportunities for women with low-grade serous ovarian cancer. | Endocr Relat Cancer | 2021 |
| 34782426 | Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. | J Immunother Cancer | 2021 |
| 34503155 | Immune-Checkpoint Inhibitors for Metastatic Colorectal Cancer: A Systematic Review of Clinical Outcomes. | Cancers (Basel) | 2021 |
| 34323412 | Tumor-derived exosomal BCYRN1 activates WNT5A/VEGF-C/VEGFR3 feedforward loop to drive lymphatic metastasis of bladder cancer. | Clin Transl Med | 2021 |
| 34012779 | Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib. | Transl Lung Cancer Res | 2021 |
| 34162658 | Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 33464691 | Gene expression comparison between primary estrogen receptor-positive and triple-negative breast cancer with paired axillary lymph node metastasis. | Breast J | 2021 |
| 32256049 | A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. | Drug Des Devel Ther | 2020 |
| 31870883 | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. | J Thorac Oncol | 2020 |
| 31713298 | Gene expression comparison between primary triple-negative breast cancer and paired axillary and sentinel lymph node metastasis. | Breast J | 2020 |
| 31682550 | Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. | J Clin Oncol | 2020 |
| 33161337 | Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio. | Breast | 2020 |
| 32366257 | circNFIB1 inhibits lymphangiogenesis and lymphatic metastasis via the miR-486-5p/PIK3R1/VEGF-C axis in pancreatic cancer. | Mol Cancer | 2020 |
| 32473302 | Prognostic gene expression signature for high-grade serous ovarian cancer. | Ann Oncol | 2020 |
| 32378480 | Non-coding RNA and immune-checkpoint inhibitors: friends or foes? | Immunotherapy | 2020 |
| 31082762 | Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy? | Breast | 2019 |
| 31378459 | Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial. | Lancet Oncol | 2019 |
| 29249801 | FOXC1-induced non-canonical WNT5A-MMP7 signaling regulates invasiveness in triple-negative breast cancer. | Oncogene | 2018 |
| 35135122 | <i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. | JCO Precis Oncol | 2018 |
| 29807697 | Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. | Gynecol Oncol | 2018 |
| 29502561 | MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. | Mayo Clin Proc | 2018 |
| 29367611 | Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. | Sci Rep | 2018 |
| 29061645 | Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. | Clin Cancer Res | 2018 |
| 27958289 | WSB1 overcomes oncogene-induced senescence by targeting ATM for degradation. | Cell Res | 2017 |
| 28132888 | Differentiation of Human Induced Pluripotent Stem Cells to Mammary-like Organoids. | Stem Cell Reports | 2017 |
| 29545915 | Characterization of primary human mammary epithelial cells isolated and propagated by conditional reprogrammed cell culture. | Oncotarget | 2017 |